700 patients109,892 observations180 daysLIVE

Patient P-02537

Synthetic patientMETA-24 · Day 170 · 45–54 · F · baseline S14Steering view · 3DOpen companion preview
Is the drug working?

Metabolic response 63 at the day-84 endpoint (observed).

Why responding?

Responding: response probability 47%, metabolic response 49 today; biology is not blocking the drug.

Is a side effect starting?

Drift detected on day 25 (HRV −11 ms, resting HR +4 bpm, sleep −0.9 h, nausea / gi symptoms +20, inflammatory load +12); the side effect would have been reported on day 80 — 55 days of warning.

Still taking it?

21 of 61 scheduled doses in the last 60 days are biologically confirmed (34%); 1 were logged but show no dose signature. Dose signature: resting HR +3 bpm, HRV −8 ms.

last 10 doses · green confirmed · amber logged only · red missed
Plan for this patient
not yet offeredrequiredowner · Study nursereview day 180Human Model →
Next action
NP-02 Dietary Support Protocol
55% probability of improvement

CGM mean 155 mg/dL and stable: dietary support targets the glucose pattern first.

Kept if

57% of 284 similar trajectories improved after NP-02; if this one does, discontinuation risk is expected to fall from 96% to ~77%. Keeping fat low is worth 4.8 GI points a day on its own. Losing this patient costs €6k; the intervention costs €45.

Daily to-dos in the companion
  • 🍽Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • 🍽Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • 💊Take the dose at the same time relative to your evening meal
  • 💊Electrolyte solution, one sachet after any loose stool
Adherence
38% worsening

Dose is being missed; nothing else works until this is fixed.

Changes the plan if

GI burden above 78 for 3 days within the onset window

LLIFE OS insight
grounded · add an LLM key for prose

P-02537 is on day 170 of META-24 (EC-03, baseline S14): response stable, tolerance deteriorating, GI unstable. Over 14 days response moved +4 and GI -1; discontinuation risk is 96%. The state is between basins, heading towards restoration, after diverging from the model on day 25.

Biology sets the gain: FUT2 non-secretor, IL6 high-expression variant, Low butyrate capacity, Low microbial diversity, Baseline state S14, Cluster EC-03 (high response / high intolerance), Adherence < 60%; butyrate capacity 31/100, diversity 2.5. Pushing it down: Escherichia coli 38.323% (LPS load) (-49.2), Low butyrate capacity (-38.7), 7 keystone species absent (-28.9). Pulling it up: Protein (supports) (+27.7). From the daily log: protein -5.4 GI next day, fat +4.8 GI next day, ultra-processed +4.5 GI next day, simple carbs +4.1 GI next day.

No action has been tried yet.

Next: NP-02 — 57% of 284 similar trajectories improved, 55% probability here. CGM mean 155 mg/dL and stable: dietary support targets the glucose pattern first. This would be contradicted by a further GI rise within the onset window or falling adherence.

Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted · dose (daily oral dose, morning)
  1. Day 0 META-24 startedBaseline state S14
  2. Day 25 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 25.

Primary contributors, last 14 days
  • Toxicity+10
  • Nutritional resilience-7
  • Inflammatory activity+3
  • Treatment adherence-2

What helped?

No interventions yet.

    LIFE OS recommendation
    55%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 57% showed improvement
    • median effect visible after 10 days
    Why this and not the default

    CGM mean 155 mg/dL and stable: dietary support targets the glucose pattern first.

    Daily trackers

    Asset settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Glucose, CGM daily mean
    CGM
    155 mg/dL
    stable · -1.2 vs previous 14 d
    Active minutes
    Wearable
    37 min
    improving · +4.0 vs previous 14 d
    Sleep duration
    Wearable
    6.4 h
    stable · +0.1 vs previous 14 d
    Energy level
    Daily log
    1.9/10
    improving · +0.3 vs previous 14 d
    Steps
    Wearable
    3,127
    improving · +189 vs previous 14 d
    GI burden
    Companion
    69.6/100
    stable · -0.7 vs previous 14 d
    Adherence
    Companion
    38.1 %
    worsening · -2.1 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards restoration · 26 from the failing basin, 73 from restoration.

    Would help
    • ME-01 Monitoring Escalation
      100% improved among 45 similar · onset 3 d · confidence 75%
    • GI-04 GI Support Protocol
      67% improved among 67 similar · onset 8 d · confidence 97%
    • NP-02 Dietary Support Protocol
      61% improved among 38 similar · onset 10 d · confidence 75%
    • More protein
      GI -5.4 next day on high-intake days · n 22
    Would not help
    • Keep fat low
      GI +4.8 next day on high-intake days · n 25
    • Keep ultra-processed low
      GI +4.5 next day on high-intake days · n 19
    • Keep simple carbs low
      GI +4.1 next day on high-intake days · n 21
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -5.4supporter · 95%
    • Dietary fat load
      +4.8detractor · 95%
    • Ultra-processed food
      +4.5detractor · 95%
    • Simple carbohydrates
      +4.1detractor · 95%
    • Insoluble fibre
      +3.4detractor · 83%
    • Alcohol
      +3.2detractor · 76%

    DeepGene damage signature

    The metagenomic + host-DNA read-out that initializes this patient's biology and, on retest, measures whether the steering worked.

    Damage score · retest day 90
    91/100
    vs baseline (day 0)
    +17
    2 improved · 17 worsened
    synthetic signature · consistent with this patient's biology
    • 4 opportunists above range: Escherichia coli, Klebsiella pneumoniae, Streptococcus gallolyticus
    • 7 keystone species absent
    • Shannon 1.34 (expected ≥ 3)
    • Butyrate production 169 CPM, below range
    • 12 resistance genes
    • Host DNA fragmentation atypical
    • Tissue recycling index 73
    Pathogens / opportunists4/5
    from 3
    Keystone species7/8
    from 4
    Diversity2/2
    Metabolic modules2/4
    from 0
    Vitamin synthesis6/7
    from 4
    Oral translocation1/1
    Host DNA1/1
    from 0
    Tissue recycling1/1
    Central mechanisms2/2
    Virulence factors7/7
    from 4
    Antibiotic resistance genes12/12
    from 8
    Genetic predisposition2/2
    Opportunists above range
    Escherichia coli 38.323% AR
    Klebsiella pneumoniae 11.497% AR
    Streptococcus gallolyticus 3.832% AR
    Clostridioides difficile 3.832% AR
    Keystone species absent
    Akkermansia muciniphila, Bifidobacterium longum, Butyricicoccus pullicaecorum, Eubacterium rectale, Faecalibacterium prausnitzii
    Capacity
    Shannon 1.34 · butyrate 169 CPM · SCFA 422
    6 vitamins below
    Host & mechanisms
    host DNA fragmentation atypical
    tissue recycling 73/100
    oral translocation 8.67% AR
    molecular_mimicry above
    estrobolome above
    12 resistance genes · 7 virulence factors

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Autonomic recovery 65
      • WearableResting HR 81 bpm
      • Wearable3,127 steps/day
      • WearableShort sleep window
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 31/100
      • Daily logFibre intake low in recent food logs
    • Mucosal barrier integrity 50
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 70 and rising
    • Inflammatory signalling 50
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 65
    • Drug metabolism and exposure 20
      • BloodToxicity index 53
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Rapid metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 2.5 · butyrate capacity 31/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisNormal
    • Bifidobacterium longumLow
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    50 ms
    Sleep
    6.4 h
    Steps
    3,238
    Resting HR
    79 bpm
    Daily log: GI score 70, nutritional resilience 28, adherence 38.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0253459%S14NP-02improved51
    P-0207657%S14SC-12improved48
    P-0265649%S14ME-01improved40
    P-0236946%S14SC-12improved47
    P-0250646%S10ME-01improved41
    P-0202845%S16ME-01improved49
    P-0241545%S05ME-01improved42
    P-0226244%S11NP-02improved46
    P-0258143%S14SC-12improved47
    P-0262843%S14SC-12improved48
    P-0223942%S16NP-02improved44
    P-0266742%S14ME-01improved45